OakChart

Scinai Immunotherapeutics Ltd ADR

SCNIHealthcare·Biotechnology·Israel·Nano·NASD·Nov 11 • 10:26 AM ET

0.4780-0.0070 (-1.43%)
2026-11-11 16:33 CET
Market cap
0.66 USD m
Revenue, TTM
3.06 USD m
Net income, TTM
-2.50 USD m
Free cash flow, TTM
-7.33 USD m
EPS diluted, TTM
-2.90
P/E
-
Compare

Price

SCNI against its 20, 50 and 200-day averages
2050200
0.002.505.007.5010.0032.0M64.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SCNIclose 0.4820-day 0.5650-day 1.16200-day 4.100.48

96.9% under the 52-week high of 15.50 on 3 Nov 2025. Last 15 sessions, 64.6% high to low

Profile

SCNI
52-week range, 1% of the way up
0.3913.00

Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.

Employees45
IPOMay 12, 2015
Beta2.24
ATR, 14d0.11
Rel volume0.06
Short float2.66%
Insider own2.25%
Inst own1.31%

Snapshot

6 groups

Valuation

Index-
Market Cap0.65M
Enterprise Value7.76M
Income-2.50M
Sales3.06M
Book/sh3.76
Cash/sh1.41
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees45
IPOMay 12, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S0.21
P/B0.13
P/C0.34
P/FCF-
EV/EBITDA-
EV/Sales2.53
Quick Ratio1.23
Current Ratio1.23
Debt/Eq0.32
LT Debt/Eq0.28
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.90
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y51.07% 21.04%
Sales past 3/5Y- -
EPS Y/Y TTM94.98%
Sales Y/Y TTM143.06%
EPS Q/Q53.93%
Sales Q/Q563.79%
EarningsNov 05 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own2.25%
Insider Trans0.00%
Inst Own1.31%
Inst Trans146.13%
ROA-18.38%
ROE-27.22%
ROIC-18.18%
Gross Margin-
Oper. Margin-244.54%
Profit Margin-81.60%
SMA20-14.49%
SMA50-58.76%
SMA200-88.35%
Trades-

Technical

Shs Outstand1.35M
Shs Float1.32M
Short Float2.66%
Short Ratio0.02
Short Interest0.04M
52W High13.00 -96.32%
52W Low0.39 22.53%
Volatility12.68% 17.43%
ATR (14)0.11
RSI (14)26.94
Beta2.24
Rel Volume0.06
Avg Volume2.12M
Volume27,324

Performance

Perf Week6.51%
Perf Month-61.14%
Perf Quarter-80.08%
Perf Half Y-90.55%
Perf YTD-93.29%
Perf Year-95.65%
Perf 3Y-99.26%
Perf 5Y-99.98%
Perf 10Y-99.99%
Recom1.00
Target Price7000.00
Prev Close0.48
Price0.48
Change %-1.43%

Peers

Mkt cap
TickerCompanyMkt cap
PPBTPurple Biotech Ltd ADR2.12M
SPRCSciSparc Ltd0.77M
CANFCan-Fite Biopharma Ltd ADR4.94M
IFRXInflaRx NV176.85M
ENLVEnlivex Ltd1.82M
CMMBChemomab Therapeutics Ltd ADR9.97M
BLRXBioline Rx Ltd ADR7.72M
AKTXAkari Therapeutics Plc ADR12.56M
CLGNCollPlant Biotechnologies Ltd7.35M
ORKAOruka Therapeutics Inc7.39B

News

latest 14 of 206
  • Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands (PR Newswire)
  • Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing (PR Newswire) -9.16%
  • Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement (PR Newswire) -16.54%
  • Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement (PR Newswire) -28.46%
  • Scinai Expands CDMO Business with $5.1 Million Manufacturing Agreement as Committed Orders Rise 300% (InvestorsHub) +6.03%
  • Loading…
  • Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement (PR Newswire)
  • Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire) +8.33%
  • Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business (PR Newswire) -8.60%
  • Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum (PR Newswire)
  • Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration (PR Newswire)
  • Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives (PR Newswire) -7.71%
  • Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility (PR Newswire) -6.02%
  • Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2024Q32024-11-220.021--0.17--
2024Q12024-07-02-0.010--43.2750.00--
2023Q32023-10-310.200-94.00066.1640.000.001
2023Q22023-08-11-0.300-45.500-109.890.000.002
2023Q12023-05-15-54.500--107.390.00--
2022Q32022-11-300.290-10.00059.0170.000.001
2022Q22022-08-25-6.120-10.000-205.830.000.001
2022Q12022-06-01-5.0000.000-206.610.000.001
2021Q42022-05-0210.000--235.240.00-2
2021Q32021-11-30-6.350--195.16---
2021Q22021-08-27-9.310--256.35---
2021Q12021-06-23-6.150--188.44---

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2014FY-1,360----
2016FY-19.340-20.510-731.860.000.00
2017FY-50.000--1,9050.00-
2018FY-90.000-50.000-3,7340.000.00
2019FY-330--3,7530.00-
2020FY-10.000--116.89--
2021FY-20.000-420-876.870.000.00
2022FY-154--1.0000.00-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2023FYS2024-03-291000.000.000.00
2023FYS2024-03-281000.000.000.00
2023FYS2024-03-271000.000.000.00
2023FYS2024-03-261000.000.000.00
2023FYS2024-03-251000.000.000.00
2023FYS2024-03-241000.000.000.00
2023FYS2024-03-231000.000.000.00
2023FYS2024-03-221000.000.000.00
2023FYS2024-03-211000.000.000.00
2023FYS2024-03-201000.000.000.00
2023FYS2024-03-191000.000.000.00
2023FYS2024-03-181000.000.000.00
2023FYS2024-03-171000.000.000.00
2023FYS2024-03-161000.000.000.00

Estimate history

EPS, annual-1905.156-3733.579-3752.786-116.893-876.871-306.396-165.97159.883-35.882-2.9022
Period201720182019202020212022202320242025TTM
EPS, quarterly124.368-26.207-7.958-17.57-6.028-6.0389.574-3.662-2.777
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000000.6611.3213.06
Period201720182019202020212022202320242025TTM
Sales, quarterly0.1680.2080.5830.1910.2770.2640.4880.4681.841
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.0070.0070.0070.0120.0180.0250.0460.0850.3471.353
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0850.0850.10.1510.3470.3470.3540.571.353
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue3.061.320.660.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A-5.432.900.510.560.750.710.460.07
Gross Profit--4.11-2.24-0.51-0.56-0.75-0.71-0.46-0.07
Selling, General and Administrative Excl. Other4.763.506.449.1810.4610.0519.1121.5321.36
Research and Development1.862.395.565.205.182.6214.4218.9019.95
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-7.48-7.60-8.68-9.69-11.02-10.79-19.82-21.99-21.44
Interest Expense-0.371.440.015.083.360.344.283.78
Unusual Expense--0.00-14.92-4.01-0.710.003.593.20-0.56
Net Income Before Taxes-2.50-8.374.82-6.48-5.77-12.38-1.30-30.65-24.40
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-2.50-8.374.82-6.48-5.77-12.38-1.30-30.65-24.40
Net Income From Continuing Operations-2.50-8.374.82-6.48-5.77-12.38-1.30-30.65-24.40
Net Income-2.50-8.374.82-6.48-5.77-12.38-1.30-30.65-24.40
EPS (Recurring)-3.50-35.87-69.76-237.88-332.54-876.88109.76-3,478.56-3,793.42
EPS (Basic, Before Extraordinaries)-2.90-35.8859.88-165.97-306.40-876.87-116.89-3,752.79-3,733.58
EPS (Diluted)-2.90-35.8859.88-165.97-306.40-876.87-116.89-3,752.79-3,733.58
EBITDA-5.56-6.17-7.02-9.18-10.46-10.05-19.11-21.53-21.36
Non-Operating Income (Expense)6.63-0.400.02-0.809.621.7822.45-1.180.26
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.310.691.141.232.762.751.030.07
Price To Earnings Ratio--1.22------
Price To Sales Ratio0.331.264.08------
Gross Margin--310.68-338.75------
Operating Margin-244.54-575.29-1,312.77------
Net Margin-81.60-633.64728.88------
Shares Outstanding1.350.350.090.050.020.020.010.010.01
Market Capitalization0.660.662.852.595.5343.4232.4160.7131.17

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.840.470.490.260.280.190.580.21
Cost of Goods Sold Incl. D&A2.441.741.60-0.92-0.360.88
Gross Profit-0.60-1.27-1.11--0.64-0.23-0.67
Selling, General and Administrative Excl. Other1.340.911.351.171.240.711.791.61
Research and Development0.440.210.630.570.56-1.291.35
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.93-2.18-2.46-0.91-1.88-0.52-1.56-2.28
Interest Expense0.020.100.11-0.240.39--
Unusual Expense0.000.000.00-0.000.000.00-14.88
Net Income Before Taxes-1.95-2.043.57-2.08-2.12--1.55-2.25
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.95-2.043.57-2.08-2.12-2.63-1.55-2.25
Net Income From Continuing Operations-1.95-2.043.57-2.08-2.12-2.63-1.55-2.25
Net Income-1.95-2.043.57-2.08-2.12-2.63-1.55-2.25
EPS (Recurring)-2.74-3.579.42-5.99-6.11-17.39-8.03-148.43
EPS (Basic, Before Extraordinaries)-2.78-3.669.57-6.04-6.03-17.57-7.96-26.21
EPS (Diluted)-2.78-3.669.57-6.04-6.03-17.57-7.96-26.21
EBITDA-1.42-1.59-2.01-0.54-1.52-0.16-1.21-1.78
Non-Operating Income (Expense)0.000.256.140.240.000.000.010.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.050.060.07----0.21
Price To Earnings Ratio-----0.310.431.22
Price To Sales Ratio0.330.961.771.883.493.004.194.33
Gross Margin-32.38-272.17-228.63--231.52-38.91-323.30
Operating Margin-105.06-466.52-504.50-343.51-678.99-272.73-267.58-1,098.54
Net Margin-105.98-435.43731.49-787.40-764.49-1,378.07-265.70-1,082.52
Shares Outstanding1.350.570.350.350.350.150.100.09
Market Capitalization0.661.442.022.474.393.452.692.85

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1.812.095.0114.2217.362.9320.9820.3120.56
Short Term Receivables0.070.080.330.110.330.370.190.101.13
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.170.210.110.050.000.000.000.160.00
Total Current Assets2.052.395.4514.3717.693.3121.1720.5721.69
Net Property, Plant & Equipment9.5711.0612.0312.7014.1714.2712.197.561.59
Total Investments and Advances0.000.000.000.000.140.150.140.190.25
Intangible Assets0.000.000.000.000.000.000.00-0.00
Other Assets0.000.000.000.000.000.000.010.010.00
Total Assets11.6313.4517.4727.0732.0017.7233.5128.3223.53
Short Term Debt Incl. Current Port. of LT Debt0.330.420.400.380.2519.020.200.000.00
Accounts Payable0.410.380.540.721.000.584.945.551.79
Other Current Liabilities0.851.010.851.241.070.390.350.290.19
Total Current Liabilities1.581.811.782.342.3219.995.495.831.98
Long Term Debt1.941.6620.1721.1622.161.9037.8125.250.00
Provision for Risks Charges0.000.000.000.000.030.030.030.020.02
Other Liabilities0.000.000.105.330.000.354.731.652.36
Total Liabilities3.523.4722.0428.8324.5022.2748.0632.764.36
Non-Equity Reserves0.000.000.000.000.000.004.293.922.97
Preferred Stock - Carrying Value5.635.630.000.000.000.000.000.000.00
Common Equity2.484.35-4.57-1.767.50-4.55-18.83-8.3516.20
Total Shareholders Equity8.109.98-4.57-1.767.50-4.55-18.83-8.3516.20
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity8.109.98-4.57-1.767.50-4.55-18.83-8.3516.20
Total Liabilities & Stockholders Equity11.6313.4517.4727.0732.0017.7233.5128.3223.53
Book Value Per Share7.1451.00-98.41-71.16405.75-394.19-2,881.82-1,278.182,479.29
Tangible Book Value Per Share7.1451.00-98.41-71.16405.75-394.19-2,881.82-1,278.182,479.29
Full-Time Employees453131331521252114
Price to Book Ratio0.130.66-0.962.105.79-7.13-3.22-3.731.80
Return on Assets-66.7931.17-29.11-19.55-49.78-5.06-99.12-94.11-61.74
Return on Equity-92.62178.21--201.27-838.84---621.68-84.69
Return on Invested Capital-83.3941.40-41.57-29.76-41.74--161.52-144.40-59.74
Quick Ratio1.301.323.066.157.640.173.863.5310.94
Current Ratio1.301.323.066.157.640.173.863.5310.94

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-2.48-8.374.82-6.48-5.77-12.38-1.30-30.65-24.40
Depreciation1.931.431.660.510.560.750.710.460.07
Other Funds (Non Cash)-5.790.70-12.95-2.59-2.293.32-16.279.463.45
Funds from Operations-6.34-6.24-6.48-8.56-7.51-8.31-16.86-20.72-20.88
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.750.160.11-0.790.270.73-4.23-0.914.97
Cash from Operating Activities-7.09-6.08-6.37-9.36-7.24-7.58-21.09-21.63-15.91
Capital Expenditures-0.24-0.02-0.01-0.64-0.83-0.13-1.78-2.09-6.60
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses2.760.000.000.000.000.010.050.000.04
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.00-0.00
Other Sources0.000.000.000.000.000.010.010.060.04
Cash from Investing Activities2.52-0.02-0.01-0.64-0.83-0.11-1.73-2.02-6.52
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock3.375.823.461.086.7521.364.3519.770.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock3.375.823.461.086.7521.364.3519.770.00
Proceedsfrom Stock Options1.045.822.010.145.8221.360.0019.720.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.004.3023.45
Change in Long Term Debt0.000.000.000.000.000.000.004.3023.45
Issuance of Long Term Debt0.000.000.000.000.000.000.004.3023.45
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities3.375.823.461.086.7520.983.9923.9223.45
Exchange Rate Effect-0.00-0.01-0.27-1.970.520.50-1.230.23
Net Change in Cash-1.25-0.29-2.93-9.18-3.2913.81-18.33-0.961.25
Free Cash Flow-7.33-6.10-6.38-9.99-8.07-7.71-22.88-23.71-22.51
Preferred Dividends (Cash Flow)---0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments1.912.853.111.81-1.13
Short Term Receivables0.200.070.150.07-0.14
Inventories0.000.000.000.00-0.00
Other Current Assets0.300.560.350.17-0.24
Total Current Assets2.413.493.612.05-1.51
Net Property, Plant & Equipment13.1713.6913.979.57-10.33
Total Investments and Advances0.000.000.000.00-0.00
Intangible Assets0.000.000.000.00-0.00
Other Assets0.120.000.000.00-0.00
Total Assets15.7017.1717.5911.63-11.84
Short Term Debt Incl. Current Port. of LT Debt0.370.370.350.33-0.50
Accounts Payable0.670.840.780.41-0.66
Other Current Liabilities0.921.021.550.85-0.96
Total Current Liabilities1.962.232.691.58-2.12
Long Term Debt3.023.213.141.94-1.86
Provision for Risks Charges0.000.000.000.00-0.00
Other Liabilities0.000.000.000.00-0.00
Total Liabilities4.985.445.833.52-3.98
Non-Equity Reserves0.000.000.000.00-0.00
Preferred Stock - Carrying Value5.635.635.635.63-5.63
Common Equity5.096.106.132.48-2.23
Total Shareholders Equity10.7111.7311.768.10-7.86
Accumulated Minority Interest0.000.000.000.00-0.00
Total Equity10.7111.7311.768.10-7.86
Total Liabilities & Stockholders Equity15.7017.1717.5911.63-11.84
Book Value Per Share3.7610.7117.357.14-14.73
Tangible Book Value Per Share3.7610.7117.357.14-14.73
Full-Time Employees---45--
Price to Book Ratio0.130.240.331.00-1.55
Return on Assets--18.38--66.82-30.40
Return on Equity--27.22--92.67-1,413.41
Return on Invested Capital-14.20-13.6323.94-20.67--27.09
Quick Ratio1.231.561.351.30-0.71
Current Ratio1.231.561.351.30-0.71

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-1.98-1.983.57-2.08-2.12-2.62
Depreciation0.520.590.450.360.360.36
Other Funds (Non Cash)0.08-0.25-6.080.45-0.060.30
Funds from Operations-1.38-1.64-2.06-1.27-1.82-1.96
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.48-0.860.60-0.01-0.380.40
Cash from Operating Activities-1.86-2.50-1.45-1.28-2.20-1.56
Capital Expenditures-0.11-0.11-0.00-0.01-0.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.010.032.740.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.00-
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.13-0.092.74-0.01-0.00-0.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00---0.000.00
Change in Capital Stock1.042.330.01-0.014.231.49
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.042.330.01-0.014.231.49
Proceedsfrom Stock Options1.05-0.010.01-0.014.231.49
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.042.330.01-0.014.231.49
Exchange Rate Effect0.00---0.050.01-
Net Change in Cash-0.95-0.251.30-1.352.03-0.03
Free Cash Flow-1.98-2.61-1.46-1.29-2.20-1.56

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 658.00K 2025: 1.31M
Israel2024: 658.00K 2025: 1.31M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.66%0.0M1.3M2.12M
2026-10-1526.04%0.2M0.7M2.11M
2026-09-302.88%0.0M0.7M1.10M
2026-09-1565.45%0.5M0.7M819.92K
2026-08-311.19%0.0M0.7M66.02K
2026-08-14-0.0M-49.73K
2026-07-311.20%0.0M0.4M41.39K
2026-07-1511.76%0.0M0.4M369.91K
2026-06-300.78%0.0M0.3M350.52K
2026-06-152.58%0.0M0.3M339.99K
2026-05-292.88%0.0M0.3M335.50K
2026-05-154.66%0.0M0.3M331.85K
2026-04-3018.95%0.1M0.3M334.75K
2026-04-152.15%0.0M0.3M5.36K
2026-03-312.45%0.0M0.3M4.21K
2026-03-139.06%0.0M0.1M5.33K
2026-02-275.58%0.0M0.1M4.90K
2026-02-130.23%0.0M0.1M4.96K
2026-01-306.31%0.0M0.1M5.55K
2026-01-150.82%0.0M0.1M5.73K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10424B3SEC
2026-11-09EFFECTEffectiveness filing by commission orderSEC
2026-11-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-09SEC
2026-10-28F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-10-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-20SEC
2026-10-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-16SEC
2026-10-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-15SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-10-05EFFECTEffectiveness filing by commission orderSEC
2026-09-24F-1Registration statement for certain foreign private issuersSEC
2026-09-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-21SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-08-28EFFECTEffectiveness filing by commission orderSEC
2026-08-27POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-08-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-19SEC
2026-07-09SCHEDULE 13G/ASEC
2026-07-01SCHEDULE 13G/ASEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-17SEC
2026-06-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-15SEC
2026-06-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-08SEC
2026-05-19EFFECTEffectiveness filing by commission orderSEC
2026-05-19424B3SEC
2026-05-15CORRESPSEC
2026-05-14UPLOADUpload SubmissionSEC
2026-05-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-12SEC
2026-05-08F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-05-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
CITADEL ADVISORS LLC1.76%
ARMISTICE CAPITAL, LLC1.02%
Virtu Financial LLC0.55%
XTX Topco Ltd0.47%
StoneX Group Inc.0.37%
HRT FINANCIAL LP0.34%
CAPTRUST FINANCIAL ADVISORS0.34%
RHUMBLINE ADVISERS0.19%
UBS Group AG0.11%
ROYAL BANK OF CANADA0.02%

Funds

Fund% owned
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF0.00%

OakChart. SCNI. Cached 15 minutes.

Some panels did not load: ratings, insider.